RECENT NEWS

Nicolas Shiaelis and Dr Nicole Robb, Oxford University scientists and co-founders of health technology company Pictura Bio, have developed a world-first diagnostic test, powered by artificial intelligence, that can identify known respiratory viruses such as influenza and COVID-19 within five minutes from just one nasal or throat swab.

Health Education England has published a capability framework that will allow for the health and care workforce to build up skills in artificial intelligence and digital healthcare technologies.

Roquefort Therapeutics has signed an exclusive licence and royalty agreement, for the field of medical diagnostics only, with Randox Laboratories, in relation to its Midkine antibody portfolio.

Tens of thousands of patients across the country will benefit from quicker access to tests, with 19 new community diagnostic centres (CDCs) which will perform 1.1 million tests, checks and scans every year set to open later this year.

The laboratory world will meet in Hannover on 9 – 11 May at Labvolution, the European trade fair for laboratory technology and optimised laboratory workflows.

Beckman Coulter Diagnostics and MeMed have announced a strategic partnership to jointly develop and commercialise the proven MeMed BV test, a host immune response diagnostic that is able to distinguish between bacterial and viral infections.

VolitionRx’s Nu.Q vet cancer test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation.

Tasso has announced that the TassoOne Plus, a new high-volume liquid blood collection device, has received CE mark certification and successfully fulfilled all of the performance, safety, and relevant product requirements under the new European Union Medical Device Regulation.

France-based start-up Previa Medical says it has raised €2.1 million in seed funding for SEPSI-SCORE, a specialist AI-based solution designed to improve the early detection of sepsis in healthcare facilities.

Beckman Coulter Life Sciences will have a full team of dedicated professionals and informative programming at the upcoming Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition, focussing on highlighting the benefits of automation to improve laboratory workflows.

IT professionals across health and social care are being invited to have their say over future plans for the IT systems that underpin the NHS.

Terumo Blood and Cell Technologies has announced US Food and Drug Administration (FDA) clearance and official launch of its IMUGARD WB Platelet Pooling Set, which supports extended shelf life of whole blood-derived platelets from five days to seven days.

Sophia Genetics is partnering with AstraZeneca to apply its multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio.

Bio-Rad Laboratories has launched StarBright Blue-series and StarBright Yellow-series dyes to provide greater flexibility in conventional and full spectrum flow cytometry applications.

Roche has announced that it has expanded its collaboration with Janssen Biotech, to create companion diagnostics for targeted therapies, further strengthening research and innovation activities.

Homerton Hospital’s new Essential Services Laboratory was opened this week by Chief Executive Louise Ashley and Chair Sir John Gieve in a ribbon cutting ceremony.

Aiforia has received a contract award to provide artificial intelligence solutions for 25 NHS Trusts’ pathology departments in the UK to support the diagnosis of patients.

Ibex Medical Analytics has announced that Galen Prostate is now CE marked under the In Vitro Diagnostic Medical Devices Regulation (IVDR) for supporting pathologists in primary diagnosis of prostate biopsies. Galen Prostate is the first standalone AI-based cancer diagnostics product of its kind certified under the IVDR.

Aptamer Group, the developer of novel Optimer binders to enable innovation in the life sciences industry, has announced a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies.

Point-of-care molecular diagnostics company Genedrive has announced that the UK’s National Institute for Health and Care Excellence (NICE) has preliminarily recommended that the Genedrive MT-RNR1 ID Kit can be used by the NHS following the evidence review as part of its Early Value Assessment (EVA) Programme.